Key facts
- This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Turnstone Biologics Corp. (TSBX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 Aug 2025, 17:22.
ORBIMED ADVISORS LLC - 08 Aug 2025 Form 4 Insider Report for Turnstone Biologics Corp. (TSBX)
- Reporting relationship
- Director
- Issuer ticker
- TSBX
- Reported as of
- 08 Aug 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Aug 2025, 17:22:13 UTC
- Prior SEC filing
- 30 Jul 2025
- Next SEC filing
- 02 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ORBIMED ADVISORS LLC filed Form 4 for Turnstone Biologics Corp. (TSBX) on 12 Aug 2025.
Change
- Previous filing in this sequence was filed on 30 Jul 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (2)
CIK 0001055951
Primary reporting owner
ORBIMED ADVISORS LLC
- Relationship
- Director
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
- Signature date
- 12 Aug 2025
CIK 0001682115
OrbiMed Capital GP VI LLC
- Relationship
- Director
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Capital GP VI LLC
- Signature date
- 12 Aug 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TSBX
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -3,099,265
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 08 Aug 2025
- Ownership
- See Footnote
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.
Footnote F2
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.
Footnote F3
This report on Form 4 is jointly filed by OrbiMed Advisors and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Rishi Gupta ("Gupta"), an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gupta is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.